Coherus BioSciences Inc
NASDAQ:CHRS
Intrinsic Value
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. [ Read More ]
The intrinsic value of one CHRS stock under the Base Case scenario is 11.84 USD. Compared to the current market price of 1.93 USD, Coherus BioSciences Inc is Undervalued by 84%.
Valuation Backtest
Coherus BioSciences Inc
Run backtest to discover the historical profit from buying and selling CHRS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Coherus BioSciences Inc
Current Assets | 508.4m |
Cash & Short-Term Investments | 117.7m |
Receivables | 260.5m |
Other Current Assets | 130.1m |
Non-Current Assets | 121.2m |
Intangibles | 71.7m |
Other Non-Current Assets | 49.6m |
Current Liabilities | 169.6m |
Accrued Liabilities | 169.6m |
Non-Current Liabilities | 653.4m |
Long-Term Debt | 473.4m |
Other Non-Current Liabilities | 180m |
Earnings Waterfall
Coherus BioSciences Inc
Revenue
|
257.2m
USD
|
Cost of Revenue
|
-159m
USD
|
Gross Profit
|
98.3m
USD
|
Operating Expenses
|
-301.5m
USD
|
Operating Income
|
-203.2m
USD
|
Other Expenses
|
-34.7m
USD
|
Net Income
|
-237.9m
USD
|
Free Cash Flow Analysis
Coherus BioSciences Inc
CHRS Profitability Score
Profitability Due Diligence
Coherus BioSciences Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Coherus BioSciences Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
CHRS Solvency Score
Solvency Due Diligence
Coherus BioSciences Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Coherus BioSciences Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CHRS Price Targets Summary
Coherus BioSciences Inc
According to Wall Street analysts, the average 1-year price target for CHRS is 10.64 USD with a low forecast of 4.04 USD and a high forecast of 24.15 USD.
Ownership
CHRS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CHRS Price
Coherus BioSciences Inc
Average Annual Return | -10.15% |
Standard Deviation of Annual Returns | 27.71% |
Max Drawdown | -93% |
Market Capitalization | 214.9m USD |
Shares Outstanding | 111 364 000 |
Percentage of Shares Shorted | 24.88% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 332 full-time employees. The company went IPO on 2014-11-06. The firm is focused on the research, development and commercialization of immunotherapies to treat cancer. The company operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis biosimilar candidate in-licensed for commercial rights in the United States and Canada from Bioeq, and a bevacizumab (Avastin) biosimilar in-licensed for commercial rights in the United States from Innovent Biologics (Suzhou) Co., Ltd. The company is also developing an internal immuno-oncology pipeline in preclinical and translational science, bioinformatics, analytical characterization, process science engineering, and clinical-regulatory development and commercialization.
Contact
IPO
Employees
Officers
The intrinsic value of one CHRS stock under the Base Case scenario is 11.84 USD.
Compared to the current market price of 1.93 USD, Coherus BioSciences Inc is Undervalued by 84%.